BioCentury
ARTICLE | Company News

Medivir, J&J in dengue deal

February 15, 2011 1:56 AM UTC

Medivir AB (SSE:MVIR B) partnered with Johnson & Johnson (NYSE:JNJ) to discover and develop dengue NS3 protease inhibitors to prevent and to treat dengue virus infection. J&J and Medivir will split research costs equally. Medivir has an option to continue contributing half of the funding for further development. If both companies remain in the collaboration through product approval, J&J will be responsible for commercialization and Medivir will be eligible for royalties. ...